Skip Navigation

COVID-19 Update

Find a Doctor

Find a Researcher

Researchers

Jean Heather Hoffman-Censits, M.D.

Photo of Dr. Jean Heather Hoffman-Censits, M.D.
  • Co-leader, Women’s Bladder Cancer Program, Greenberg Bladder Cancer Institute
  • Assistant Professor of Oncology
Female

Expertise

Hematology, Medical Oncology

Research Interests

Urothelial cancers; Small cell bladder cancer; Women’s bladder cancer

Locations

The Bunting Blaustein Cancer Research Building

1650 Orleans Street
Baltimore, MD 21287 map
Phone: 443-287-5654 | Fax: 410-614-8397

Background

Dr. Jean Hoffman-Censits is a genitourinary cancer specialist in Baltimore, caring for patients with urothelial cancers of the bladder and upper tract. She serves as co-leader of the Women’s Bladder Cancer Program in the Greenberg Bladder Cancer Institute at the Johns Hopkins University School of Medicine.

Dr. Hoffman-Censits received her undergraduate degree in neuroscience from Trinity College. She earned her M.D. degree from the Sidney Kimmel Medical College of Thomas Jefferson University. She completed her residency at Thomas Jefferson University Hospital and performed a fellowship in hematology and oncology at Temple University Medical Center. She joined the Johns Hopkins faculty in 2018.

Dr. Hoffman-Censits's research interests focus on urothelial cancers. Her clinical research has helped identify urothelial cancer sub-types and establish new treatments for bladder and upper tract urothelial cancers.

She is a member of the American Medical Association, the American Society of Clinical Oncology, the American Urological Association and the Society for Immunotherapy of Cancer.

...read more

Titles

  • Co-leader, Women’s Bladder Cancer Program, Greenberg Bladder Cancer Institute
  • Assistant Professor of Oncology
  • Assistant Professor of Urology

Departments / Divisions

Centers & Institutes

Education

Degrees

  • MD, Sidney Kimmel Medical College of Thomas Jefferson University (2002)

Residencies

  • Thomas Jefferson University Hospital / Internal Medicine (2006)

Fellowships

  • Temple University Medical Center / Hematology and Oncology (2009)

Board Certifications

  • American Board of Internal Medicine / Medical Oncology (2009)

Research & Publications

Research Summary

Dr. Jean Hoffman-Censits’ research focus is in urothelial cancers. She has had major roles in trials that have established neoadjuvant ddMVAC as a standard therapy for bladder cancer, and which have led to two FDA approvals of Atezolizumab for bladder cancer. Dr. Jean Hoffman-Censits is co-principal investigator on the first major chemotherapy trial in upper tract cancer and has designed a follow-up trial to test immune checkpoint blockade prospectively in this population. She is designing a program in small cell bladder cancer, a rare but aggressive subtype with little prospective data. She is also designing a clinical and research program focused on women’s bladder cancer; although men outnumber women five to one in bladder cancer incidence, women have a worse prognosis.

Clinical Trial Keywords

Urothelial cancers, Small cell bladder cancer, Women’s bladder cancer

Clinical Trials

Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN)

Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer

Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations

Selected Publications

Pal, SK, Bajorin, D, Dizman, N, Hoffman-Censitis, J, Quinn, D, Petrylak, D, Galsky, M, Vaishampayan, U, De Giorgi, U, Gupta, S, Burris, H, Soifer, H, Li, G, Wang, H, Dambkowski, C, Moran,S Daneshmand, S, Rosenberg, J. "Infigratinib in Upper Tract Urothelial Carcinoma Versus Urothelial Carcinoma of the Bladder and Association with Comprehensive Genomic Profiling/Cell-free DNA Results." Cancer. Accepted for publication, 2020.

Benjamin Miron, MDa, Jean H. Hoffman-Censits, MDb, Fern Anari, MDa, John O'Neilla, Daniel M. Geynisman, MDa, Matthew R. Zibelman, MDa, Alexander Kutikov, MD a, Rosalia Viterbo, MDa, Richard E. Greenberg, MDa, David Chen, MDa, Costas D. Lallas, MDc, Edouard John Trabulsi, MDc, R. Katherine Alpaugh, PhDa, Essel Dulaimi, MDa, Erica A. Golemis, PhDa, Robert Uzzo, MDa, Eric A. Ross, PhDa, Elizabeth R. Plimack, MDa. "Defects in DNA Repair Genes Confer Improved Long-term Survival after Cisplatin-based Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer." European Urology Oncology. Accepted for publication, 2020 February.

Hoffman-Censits, J, Choi, W, Pal, S, Trabulsi, E, Kelly, W, Hahn, N, Comperat, E, Matoso, A, Cussenot, O, Cancel-Tassin, G, Fong, M, Ross, J, Madison, R, Ali, S. "Urothelial Cancers with Small Cell Variant Histology Have Confirmed High Tumor Mutational Burden, Frequent TP53 and RB Mutations, and a Unique Gene Expression Profile." European Urology Oncology. 2020 February.

Vitaly Margulis, MD, Maneka Puligandla, MS, Edouard J. Trabulsi, MD, FACS, Elizabeth R. Plimack, MD, Elizabeth R. Kessler, MD, Surena F. Matin, MD, Guilherme Godoy, MD, Ajjai Alva, MD, Noah M. Hahn, MD, Michael A. Carducci, MD, Jean Hoffman-Censits, MD, and Collaborators. "Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery for Patients with High Grade Upper Tract Urothelial Carcinoma." Journal of Urology. 2019 Nov 8.

Pal SK, Hoffman-Censits J, Zheng H, Kaiser C, Tayama D, Bellmunt J. "Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Clinical Experience from an Expanded Access Study in the United States." Eur Urol. 2018 May;73(5):800-806.

Academic Affiliations & Courses

Courses and Syllabi

  • Bladder Cancer for 2019, Lecturer, Oncology Fellows Johns Hopkins University
    2019
  • Trials in Advanced Bladder Cancer, Lecturer, Sibley Memorial Hospital
    2019
  • Trials in Advanced Bladder Cancer, Lecturer, Johns Hopkins Hospital
    2018

Activities & Honors

Honors

  • Faculty Team Achievement Award, Sidney Kimmel Medical College, 2016

Memberships

  • Society for Immunotherapy of Cancer, 2017
  • American Urological Association, 2010
  • American Medical Association, 2009
  • American Society of Clinical Oncology, 2006

Patient Ratings & Comments

The Patient Rating score is an average of all responses to physician related questions on the national CG-CAHPS Medical Practice patient experience survey through Press Ganey. Responses are measured on a scale of 1 to 5, with 5 being the best score. Comments are also gathered from our CG-CAHPS Medical Practice Survey through Press Ganey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

  • ...Loading ratings...
  • ... 
  • ... 
  • ... 
  • ... 
  • ... 

Comments

Loading...
Is this you? Edit Profile
back to top button